Fruquintinib + Placebo
Phase 3Completed 1 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Fruquintinib + Placebo
Fruquintinib + Placebo is a phase 3 stage product being developed by HUTCHMED for NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT02691299. Target conditions include NSCLC.
What happened to similar drugs?
7 of 20 similar drugs in NSCLC were approved
Approved (7) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04322539 | Phase 3 | Completed |
| NCT02691299 | Phase 3 | Completed |
| NCT02314819 | Phase 3 | Completed |
| NCT02590965 | Phase 2 | Completed |
| NCT02196688 | Phase 2 | Completed |
Competing Products
20 competing products in NSCLC